AB-MDMSBA

AB-MDMSBA
Legal status
Legal status	DE: NpSG (Industrial and scientific use only);
Identifiers
	IUPAC name N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-3-(dimethylsulfamoyl)-4-methylbenzamide;
PubChem CID	172872001;
ChemSpider	129395436;
Chemical and physical data
Formula	C15H23N3O4S
Molar mass	341.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=C(C=C1)C(=O)N[C@@H](C(C)C)C(=O)N)S(=O)(=O)N(C)C;
	InChI InChI=InChI=1S/C15H23N3O4S/c1-9(2)13(14(16)19)17-15(20)11-7-6-10(3)12(8-11)23(21,22)18(4)5/h6-9,13H,1-5H3,(H2,16,19)(H,17,20)/t13-/m0/s1; Key:KYNAATZHNRULED-ZDUSSCGKSA-N;

AB-MDMSBA is a novel synthetic compound that has been sold as a designer drug. It has been detected by drug checking services in Australia and New Zealand being misrepresented as a benzodiazepine.^[1]^[2]

It is structurally similar to other arylsulfonamide-based synthetic cannabinoids such as QMPSB.^[3] This class of synthetic cannabinoid has previously been targeted toward greater selectivity of the cannabinoid receptor CB₂ over CB₁.^[4] The activity of AB-MDMSBA against either cannabinoid receptor is unknown.

References

^ "Synthetic cannabinoid AB-MDMSBA found in 'benzodiazepine' samples - The Know". theknow.org.au. 2024-12-10. Retrieved 2025-06-10.
^ "New synthetic cannabinoid misrepresented as a benzodiazepine". High Alert. Retrieved 2025-06-10.
^ Lebon F, Christophe B, Burton M, De Ryck M, Quéré L, Lambeng N (January 2007). "Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: Identification of a lead and initial SAR studies". Bioorganic & Medicinal Chemistry Letters. 17 (1): 272–277. doi:10.1016/j.bmcl.2006.09.049. PMID 17027269.
^ Ajello CW, Worm K, Bourdonnec BL, Savolainen MA, O'Hare H, Cassel JA, Stabley GJ, DeHaven RN, LaBuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE, Goodman AJ (January 2009). "CB2 selective sulfamoyl benzamides: Optimization of the amide functionality". Bioorganic & Medicinal Chemistry Letters. 19 (2): 309–313. doi:10.1016/j.bmcl.2008.11.091. PMID 19091565.

[1] "Synthetic cannabinoid AB-MDMSBA found in 'benzodiazepine' samples - The Know". theknow.org.au. 2024-12-10. Retrieved 2025-06-10.

[2] "New synthetic cannabinoid misrepresented as a benzodiazepine". High Alert. Retrieved 2025-06-10.

[3] Lebon F, Christophe B, Burton M, De Ryck M, Quéré L, Lambeng N (January 2007). "Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: Identification of a lead and initial SAR studies". Bioorganic & Medicinal Chemistry Letters. 17 (1): 272–277. doi:10.1016/j.bmcl.2006.09.049. PMID 17027269.

[4] Ajello CW, Worm K, Bourdonnec BL, Savolainen MA, O'Hare H, Cassel JA, Stabley GJ, DeHaven RN, LaBuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE, Goodman AJ (January 2009). "CB2 selective sulfamoyl benzamides: Optimization of the amide functionality". Bioorganic & Medicinal Chemistry Letters. 19 (2): 309–313. doi:10.1016/j.bmcl.2008.11.091. PMID 19091565.

[1]

[2]

[3]

[4]

See also

References